Fosun Pharmaceutical Unit Wins China Approval for Norepinephrine Injection

MT Newswires Live

01/23

Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) said a subsidiary has received China regulatory approval for norepinephrine bitartrate injection, according to a Thursday Hong Kong bourse filing.

Hong Kong-listed shares of the pharmaceutical firm were up nearly 2% in Friday morning trade.

The drug, developed by Jinzhou Avanc Pharmaceutical, was approved by the National Medical Products Administration for restoring blood pressure in acute hypotensive states, cardiac arrest, and shock, including as supportive treatment during resuscitation.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2605428345"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2605428345\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2605428345?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-23 11:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605428345","market":"sg","top_or_hot":-1,"title":"Fosun Pharmaceutical Unit Wins China Approval for Norepinephrine Injection","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical (HKG:2196, SHA:600196) said a subsidiary has received China regulatory approval for norepinephrine bitartrate injection, according to a Thursday Hong Kong bourse filing.</p><p>Hong Kong-listed shares of the pharmaceutical firm were up nearly 2% in Friday morning trade.</p><p>The drug, developed by Jinzhou Avanc Pharmaceutical, was approved by the National Medical Products Administration for restoring blood pressure in acute hypotensive states, cardiac arrest, and shock, including as supportive treatment during resuscitation.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharmaceutical Unit Wins China Approval for Norepinephrine Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharmaceutical Unit Wins China Approval for Norepinephrine Injection\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-01-23 11:38</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical (HKG:2196, SHA:600196) said a subsidiary has received China regulatory approval for norepinephrine bitartrate injection, according to a Thursday Hong Kong bourse filing.</p><p>Hong Kong-listed shares of the pharmaceutical firm were up nearly 2% in Friday morning trade.</p><p>The drug, developed by Jinzhou Avanc Pharmaceutical, was approved by the National Medical Products Administration for restoring blood pressure in acute hypotensive states, cardiac arrest, and shock, including as supportive treatment during resuscitation.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"復星醫藥","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2605428345","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605428345","pubTimestamp":1769139484,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Fosun Pharmaceutical  said a subsidiary has received China regulatory approval for norepinephrine bitartrate injection, according to a Thursday Hong Kong bourse filing.Hong Kong-listed shares of the pharmaceutical firm were up nearly 2% in Friday morning trade.The drug, developed by Jinzhou Avanc Pharmaceutical, was approved by the National Medical Products Administration for restoring blood pressure in acute hypotensive states, cardiac arrest, and shock, including as supportive treatment during resuscitation.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","02196":"复星医药","BK0188":"融资融券","BK0175":"白马股","BK1593":"医美概念股","BK0012":"证金概念","BK0196":"行业龙头","BK0060":"抗癌","BK1515":"抗疫概念","BK0187":"一线龙头","BK1191":"制药","BK0028":"国家队","BK0239":"医药制造","BK0183":"MSCI概念","BK0096":"民营医院"},"translate_title":"复星医药子公司去甲肾上腺素注射液获中国批件","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"02196":0.9},"content_text":"Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) said a subsidiary has received China regulatory approval for norepinephrine bitartrate injection, according to a Thursday Hong Kong bourse filing.Hong Kong-listed shares of the pharmaceutical firm were up nearly 2% in Friday morning trade.The drug, developed by Jinzhou Avanc Pharmaceutical, was approved by the National Medical Products Administration for restoring blood pressure in acute hypotensive states, cardiac arrest, and shock, including as supportive treatment during resuscitation.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}